Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089829 | 0.81 | GSK3B (0.46) | GSK3BMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12207252 | 0.81 | GSK3B (0.57) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL12207381 | 0.78 | GSK3B (0.52) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL497227 | 0.78 | GSK3B (0.52) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL1673943 | 0.78 | GSK3B (0.52) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL21019936 | 0.77 | MEN1 (0.45) | GSK3BMAPK13MAPK12MAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL3819113 | 0.76 | GSK3B (0.51) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL19806120 | 0.75 | SYK (0.43) | PIK3CA | |
| SCHEMBL2488368 | 0.74 | GSK3B (0.49) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL7385338 | 0.74 | GSK3B (0.59) | GSK3BCDC7ROCK2MAP4K4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2057141-A1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| WO-2008023239-A1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | disclosed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | disclosed |
| US-7049318-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1654250-A1 | SUBSTITUTED PYRIDONES AND PYRIMIDINONES WITH ANTIINFLAMMATORY PROPERTIES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2005012286-A1 | SUBSTITUTED PYRIDONES AND PYRIMIDINONES WITH ANTIINFLAMMATORY PROPERTIES | AMGEN INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-01-27 | — | — | US | disclosed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | disclosed |
| EP-1136482-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors | SANOFI-SYNTHELABO (FR) | 2001-09-26 | — | — | EP | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | GSK3B 205/4885MAPK13 1988/4885MAPK12 1370/4885 |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885MAPK13 626/4885MAPK12 358/4885 |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | GSK3A, GSK3B, CSNK2A3 | GSK3B 2/4885MAPK13 313/4885MAPK12 162/4885 |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MAPK13 764/4885MAPK12 564/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | GSK3B 2369/4885MAPK13 1577/4885MAPK12 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.